STAAR Surgical (NASDAQ:STAA - Get Free Report) major shareholder Broadwood Partners, L.P. acquired 8,200 shares of the company's stock in a transaction on Wednesday, April 9th. The shares were acquired at an average price of $15.08 per share, for a total transaction of $123,656.00. Following the completion of the acquisition, the insider now directly owns 13,518,591 shares in the company, valued at $203,860,352.28. The trade was a 0.06 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Major shareholders that own 10% or more of a company's shares are required to disclose their sales and purchases with the SEC.
Broadwood Partners, L.P. also recently made the following trade(s):
- On Monday, April 7th, Broadwood Partners, L.P. acquired 138,054 shares of STAAR Surgical stock. The shares were bought at an average price of $15.61 per share, for a total transaction of $2,155,022.94.
- On Friday, April 4th, Broadwood Partners, L.P. bought 497,631 shares of STAAR Surgical stock. The stock was bought at an average cost of $15.91 per share, with a total value of $7,917,309.21.
- On Wednesday, April 2nd, Broadwood Partners, L.P. bought 31,780 shares of STAAR Surgical stock. The stock was purchased at an average price of $17.43 per share, with a total value of $553,925.40.
- On Monday, March 31st, Broadwood Partners, L.P. purchased 22,189 shares of STAAR Surgical stock. The shares were purchased at an average cost of $17.46 per share, for a total transaction of $387,419.94.
- On Thursday, March 27th, Broadwood Partners, L.P. acquired 3,620 shares of STAAR Surgical stock. The shares were purchased at an average price of $17.48 per share, for a total transaction of $63,277.60.
- On Tuesday, March 25th, Broadwood Partners, L.P. bought 34,296 shares of STAAR Surgical stock. The shares were acquired at an average price of $17.44 per share, with a total value of $598,122.24.
- On Thursday, March 20th, Broadwood Partners, L.P. acquired 108,720 shares of STAAR Surgical stock. The shares were acquired at an average price of $17.96 per share, for a total transaction of $1,952,611.20.
- On Tuesday, March 18th, Broadwood Partners, L.P. purchased 93,124 shares of STAAR Surgical stock. The stock was bought at an average cost of $17.54 per share, for a total transaction of $1,633,394.96.
- On Monday, March 3rd, Broadwood Partners, L.P. acquired 249,503 shares of STAAR Surgical stock. The stock was purchased at an average price of $16.64 per share, for a total transaction of $4,151,729.92.
- On Thursday, February 27th, Broadwood Partners, L.P. bought 259,316 shares of STAAR Surgical stock. The stock was acquired at an average price of $17.05 per share, for a total transaction of $4,421,337.80.
STAAR Surgical Stock Down 1.9 %
NASDAQ:STAA opened at $15.57 on Friday. The stock has a fifty day simple moving average of $17.79 and a 200 day simple moving average of $24.10. The firm has a market capitalization of $767.99 million, a price-to-earnings ratio of -37.98 and a beta of 0.75. STAAR Surgical has a 1-year low of $13.50 and a 1-year high of $51.81.
Wall Street Analysts Forecast Growth
A number of research firms have commented on STAA. Stifel Nicolaus dropped their price target on shares of STAAR Surgical from $38.00 to $20.00 and set a "buy" rating on the stock in a research report on Wednesday, February 12th. BTIG Research cut STAAR Surgical from a "buy" rating to a "neutral" rating in a research report on Wednesday, February 12th. StockNews.com lowered STAAR Surgical from a "hold" rating to a "sell" rating in a report on Thursday, February 13th. Needham & Company LLC reaffirmed a "hold" rating on shares of STAAR Surgical in a report on Thursday, February 27th. Finally, Stephens reissued an "equal weight" rating and issued a $17.00 price target on shares of STAAR Surgical in a report on Tuesday, March 18th. Two investment analysts have rated the stock with a sell rating, eight have given a hold rating and one has assigned a buy rating to the stock. According to data from MarketBeat.com, STAAR Surgical has a consensus rating of "Hold" and an average target price of $25.29.
Check Out Our Latest Research Report on STAA
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently made changes to their positions in STAA. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of STAAR Surgical by 3.9% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 28,123 shares of the medical instruments supplier's stock valued at $683,000 after acquiring an additional 1,044 shares in the last quarter. Quarry LP purchased a new stake in shares of STAAR Surgical in the third quarter valued at $50,000. MetLife Investment Management LLC boosted its position in shares of STAAR Surgical by 6.3% in the fourth quarter. MetLife Investment Management LLC now owns 30,396 shares of the medical instruments supplier's stock worth $738,000 after buying an additional 1,796 shares during the period. Bridgefront Capital LLC grew its holdings in shares of STAAR Surgical by 27.2% during the fourth quarter. Bridgefront Capital LLC now owns 10,792 shares of the medical instruments supplier's stock valued at $262,000 after buying an additional 2,306 shares in the last quarter. Finally, Illinois Municipal Retirement Fund grew its holdings in shares of STAAR Surgical by 8.3% during the fourth quarter. Illinois Municipal Retirement Fund now owns 30,144 shares of the medical instruments supplier's stock valued at $732,000 after buying an additional 2,318 shares in the last quarter. 96.70% of the stock is currently owned by institutional investors and hedge funds.
About STAAR Surgical
(
Get Free Report)
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
